SUMMARY

Most therapeutic targets involved in aberrant intracellular protein-protein and protein-RNA interactions remain elusive to traditional drug discovery efforts. The team led by Y. Guillén Schlippe has developed a broadly applicable discovery platform capable of identifying hits for such therapeutically “undruggable” targets.

The goal of the current project is to demonstrate that this discovery platform is capable of delivering new therapeutic lead molecules for a variety of targets involved in cancer and bacterial infections. Validation of the platform and generated hits will open the door to new therapeutic opportunities and modalities, expanding the “druggable” proteome.

PROJECT GOALS

- Validation of the discovery platform
- Identification of hits for novel therapeutic targets

LONG-TERM GOALS

- Validation of lead drug candidates
- License to Pharma or startup foundation